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Synaptic vesicle proteins 2 (SV2) were discovered in the early 80s, but the clear
demonstration that SV2A is the target of efficacious anti-epileptic drugs from the
racetam family stimulated efforts to improve understanding of its role in the brain. Many
functions have been suggested for SV2 proteins including ions or neurotransmitters
transport or priming of SVs. Moreover, several recent studies highlighted the link
between SV2 and different neuronal disorders such as epilepsy, Schizophrenia (SCZ),
Alzheimer’s or Parkinson’s disease. In this review article, we will summarize our present
knowledge on SV2A function(s) and its potential role(s) in the pathophysiology of various
brain disorders.
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SV2: BASIC FACTS
SV2A belongs to the Synaptic vesicle (SV) protein 2 family, which also includes SV2B and SV2C.
These three paralogs can be found in vesicles of neuronal or endocrine cells. All members are
composed of a highly N-glycosylated 80 kDa backbone (Table 1) organized in 12 transmembrane
(TM) regions. They also present two large loops—one cytoplasmic and one luminal—and N- and
C-terminal cytoplasmic sequences (Janz et al., 1999). SV2A is the only member of the SV2 family
ubiquitously expressed in the adult brain, and is also found in neuroendocrine cells and at
neuromuscular junctions (Buckley and Kelly, 1985; Bajjalieh et al., 1994; Dong et al., 2006).
Proteins of the SV2 family share approximately 60% of their sequences, especially around TM
and C-terminal regions. Though luminal loops differ among SV2 proteins, they always contain
at least three N-glycosylation sites and present a repeated structure of hydrophobic amino-acids
(Janz and Sudhof, 1999). The SV2 family is well conserved among vertebrates but no invertebrate
isoform has been found. However, SV2 proteins exhibit a topology related to other transporter
proteins, as their first six TM domains are homologous to the major facilitator superfamily (MFS)
to which the human glucose transporter belongs, and the other six are closer to neurotransmitter
transporters (Feany et al., 1992).
Another homologous protein is SVOP (SVtwO-related Protein; Bajjalieh et al., 1992; Janz
et al., 1998). SVOP is a non-glycosylated protein also found in SVs, rather distantly related
to SV2 proteins (only 20%–22% homology) but with a similar structure. It also contains
12 TM domains, both termini regions are cytoplasmic, but SVOP does not feature either
a long intraluminal loop or glycosylated sites. Unlike SV2 proteins, SVOP is evolutionarily
conserved in vertebrates and invertebrates. The role of SVOP is currently unknown but
its absence in SVOP KO mice does not lead to an abnormal phenotype (Yao et al., 2013).
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Expression Whole brain Whole brain except
DG, GP, RNT, SN
Central neuraxis
Synapses types GA, Gl Gl GA, D, C
Genes, mRNAs and proteins information of murine SV2A, SV2B and SV2C (http://www.informatics.jax.org; http://vega.sanger.ac.uk). DG, dentate gyrus; GP, globus
pallidus; RNT, the reticular nucleus of the thalamus; SN, subtantia nigra; GA, GABAergic; Gl, Glutamatergic; D, Dopaminergic; C, Cholinergic.
Even if SV2 proteins share the majority of their sequences,
they all have specific expression patterns. As previously said,
SV2A is found in all areas of the brain, including the trigeminal
nuclei (Edvinsson et al., 2015) and the sphenopalatine ganglion
(Steinberg et al., 2016) where it was recently found. SV2B
follows the same pattern of expression with the exception of
dentate gyrus (DG), globus pallidus (GP), the reticular nucleus
of the thalamus and the reticular part of the substantia nigra
(Bajjalieh et al., 1994; Crèvecœur et al., 2013). Finally, SV2C has
a more variable expression. It is present in the central neuraxis,
including the striatum, midbrain (especially in the substantia
nigra), and hindbrain at high level. Low levels of SV2C can be
found in the cerebrum, the olfactory bulb, the hippocampus
and the cerebellum (Dardou et al., 2011). A closer look at
certain structures of the brain emphasizes another difference
between all paralogs: SV2A can be found in glutamatergic and
GABAergic neurons, in all cortical layers of the cerebellum for
example. On the other hand, SV2B seems to be restricted to
some glutamatergic neurons, as it is found in granule cells of
the cerebellum, but is absent from DG granule cells (Bajjalieh
et al., 1994; Crèvecœur et al., 2013). SV2C is found in certain
GABAergic cell types, like Purkinje cells of the cerebellum, in
dopaminergic neurons as well as a fraction of cholinergic neurons
(Dardou et al., 2011). The specificity of SV2B and SV2C for
respectively glutamatergic and GABAergic synapses was also
observed by proteomic analysis and co-localization study of
immuno-isolated vesicles (Grønborg et al., 2010; Bragina et al.,
2012).
During the mouse development, the expression pattern of
SV2A and SV2B starts at mid-neurogenesis, at embryonic day
14 (E14). Distribution of SV2A stabilizes around birth (postnatal
day 0—P0) while that of SV2B seems to be more variable during
life (Bajjalieh et al., 1994; Crèvecœur et al., 2013). Between P5 and
P7, the amount of SV2A greatly increases specifically in the
CA1 region of the hippocampus, that of SV2B gradually raises
from P5 to P10 in the same region while that of SV2C does not
change (Crèvecœur et al., 2013). The expression of SV2C has not
been the subject of a detailed study.
The correct folding of SV2A appears to be important for its
function and proper location since many substitution mutations
give rise to diffuse or aggregated cytoplasmic locations of SV2A
(Chang and Sudhof, 2009; Nowack et al., 2010; Yao et al., 2010;
Kwon and Chapman, 2012). The exact role of N-glycosylation
of SV2 proteins is unknown. However, two SV2A mutants
(N498Q/N573Q or N548Q/N573Q double mutations) displaying
diffuse cytoplasmic localization, those N-glycosylation sites
could be implicated in folding or quality control in the
endoplasmic reticulum (Kwon and Chapman, 2012). For SV2B
and SV2C, glycosylation seems to be even more crucial as
mutants with only one modified glycosylation site (SV2B-N516A
and SV2C-N559A) show a reduction of expression whereas
SV2A-N573A shows no phenotype (Yao et al., 2016).
Little is known about the regulation of SV2A gene expression.
Prediction analysis by SABiosciences’ Text Mining Application
and UCSC’s Genome Browser identified several potential
transcription factor binding sites present on SV2A promoter,
but the functional importance of any of them has still to be
proven. Likewise, more than 70 binding sites for microRNAs
are potentially located on the SV2A mRNA sequence according
to StarBaser, but only one of them has been studied in
detail. MiR-485 is present in the hippocampus at least between
E18.5 and P20 and is able in vitro to specifically decrease SV2A
levels without affecting other synaptic proteins. Overexpression
of miR-485 or SV2A siRNA-mediated knockdown produce
similar results: a reduction of dendritic spine density, clustering
of PSD-95 and surface expression of GluR2 (Cohen et al., 2011).
However, other studies did not show any change in synaptic
density in SV2A KO mice nor in SV2A KO cortical neurons
(Crowder et al., 1999; Custer et al., 2006).
SV2A: FUNCTIONS
Effect on Neurotransmission
One of the first trials on the role of SV2A was the extreme
phenotype displayed by SV2A KO mice. Mice that survive birth
seem to be normal during their first days of life. However,
after 1–2 weeks, they experience seizures, quickly followed by
weight loss and death around P20 (Crowder et al., 1999; Janz
et al., 1999). Importantly, seizures in this KO model seem to
be more extreme than those observed in other synaptic protein
mutantmice (Janz et al., 1999). Since the whole brain architecture
is not modified, with no changes in synapse morphology or
density, it appears that the brain develops correctly, making a
developmental role for SV2A unlikely (Crowder et al., 1999;
Janz et al., 1999). On the contrary, SV2B KO mice are viable
with no apparent phenotype and SV2A/SV2B double KO (DKO)
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mice display the same phenotype as SV2A KO (Janz et al.,
1999).
From an electrophysiological point of view, SV2A KO mice
hippocampi display normal miniature Excitatory and Inhibitory
Postsynaptic Currents (mEPSC and mIPSC) frequencies. As
mPSC are inputs observed without action potentials thus
accounting for the response obtained after the release of a single
vesicle, this excludes a role of SV2A in vesicle fusion events
(Crowder et al., 1999; Janz et al., 1999; Chang and Sudhof, 2009;
Venkatesan et al., 2012). In contrast, spontaneous postsynaptic
currents (sPSC, the multiple vesicles event obtained without
any experimental stimulation of a cell) and evoked postsynaptic
currents (ePSC, the multiple vesicles event response of a cell
obtained after experimental stimulations) are affected in SV2A
KO (Figure 1). While all studies agree that the absence of
SV2A induces a reduction of the frequency and amplitude
of inhibitory postsynaptic currents (IPSC), either spontaneous
or evoked (Crowder et al., 1999; Chang and Sudhof, 2009;
Venkatesan et al., 2012), its effect on excitatory postsynaptic
currents (EPSC) is still discussed. Recording made on primary
cultured hippocampal autapses from SV2A/SV2B DKO mice
shows smaller amplitudes of eEPSC compared to SV2B KO
autapses. Following observations of a facilitation response of
SV2A/SV2B DKO neurons during trains of action potentials
and a smaller readily releasable pool of vesicles (RRP), the
author hypothesized that the function of SV2A is linked to
the release probability (Custer et al., 2006). These results are
in agreement with a previous study performed on chromaffin
cells showing a reduction of calcium-induced exocytotic bursts
and of SDS resistant SNARE complexes in absence of SV2A,
resulting in a smaller RRP (Xu and Bajjalieh, 2001). Those
two studies argue for an involvement of SV2A in vesicle
fusion competence (Xu and Bajjalieh, 2001; Custer et al.,
2006). Still, another study shows that cultured primary cortical
neurons from SV2A/SV2B DKO display synaptic facilitation
during stimulus trains but no RRP changes (Chang and
Sudhof, 2009). These authors thus exclude a priming role for
SV2A but rather argue for a Ca2+-responsiveness enhancer
role in primed vesicles (Chang and Sudhof, 2009). A more
recent electrophysiological study performed on hippocampal
slices showed that in the absence of SV2A, EPSC amplitudes
remain unchanged while the associated frequencies increase
(Venkatesan et al., 2012). The author emphasized that the
opposite effect of SV2A on excitatory and inhibitory currents
observed in hippocampal slices of SV2A KO likely underlines
an effect of SV2A on GABAergic network subsequently
impacting the Glutamatergic synapses rather than a direct effect
of SV2A on both networks. Interestingly, overexpression of
SV2A in autaptic hippocampal neurons produced the typical
neurotransmission defect observed in SV2A KO mice (Nowack
et al., 2011).
Although at first sight all these results do not seem to fit
together correctly, a closer look at all of them could help raise a
hypothesis about the role of SV2A (Figure 2). Custer, Chang and
Sudhof measured electrophysiological parameters in neurons
cultivated fromWT and KO animals. Proportionally, differences
of IPSC and EPSC amplitudes between WT and KO are similar
(±37% for EPSC, ±39% for IPSC), which could suggest that
they result from the same defect. But each system has its own
characteristics. Inhibitory synapses are usually placed closer to
the soma than excitatory synapses (Ito et al., 1997; Gulyás et al.,
1999; Magee and Cook, 2000; Megías et al., 2001; Darstein
et al., 2003; Kawakami et al., 2003; Kulik et al., 2003; Gassmann
et al., 2004), which implies that inhibitory signals are thus more
constant and control the traffic of excitatory local responses (Jaffe
and Carnevale, 1999). Moreover, at least in the hippocampus,
inhibitory synapses tend to be more robust in contrast to
excitatory synapses, which compensate failure occurrences by
a burst firing pattern (Miles and Wong, 1984, 1986). Those
observations suggest that the inhibitory system could be more
sensitive to SV2A depletion and potentially explain Venkatesan’s
results: at cellular level, the amplitude of both PSC is reduced
due to the absence of SV2A but at tissue level, the impact on
the inhibitory system is overriding. Lack of inhibitory currents
cancels its restraining role and unleashes excitatory currents,
leading to an overload of the excitatory defect and a conversion to
overall hyperactivity. This hypothesis doesn’t rule out that SV2A
might somehow be linked to Ca2+-dependent transmissions in
both glutamate and GABA networks.
Transporter
Due to the evident structural links between SV2A and
different transporters, it was first proposed that SV2A was
either a neurotransmitter-, an ion- or a glucose-transporter.
Interestingly, 3D reconstructions and structural studies based on
MFS models show that SV2A has two different conformations
with a central depression facing towards one or the other side
of the membrane, strengthening the possibilities of a transporter
activity (Lynch et al., 2008; Lee et al., 2015). The neurotransmitter
transporter hypothesis is rather unlikely because SV2A is found
in GABA and glutamate releasing synapses (Bajjalieh et al.,
1994) and is present in immune-isolated VGlut1-, VGlut2-
and VGat-containing vesicles, although its concentration may
be higher in VGat-containing vesicles (Grønborg et al., 2010;
Bragina et al., 2012). Moreover, quantal and vesicle sizes
are normal in SV2A KO, suggesting that neurotransmitter
transport is unaffected (Xu and Bajjalieh, 2001; Custer et al.,
2006). Concerning ion transport, the early identification of
two negatively charged residues in the first TM region raised
the possibility that SV2A could transport Ca2+. This issue
was also ruled out when neither the overexpression nor
the silencing of SV2A induced a modulation of cytosolic or
intravesicular Ca2+ concentration in INS-1E insulinoma cells
(Iezzi et al., 2005), although those measurements were obtained
in a non-physiological system. Furthermore, these results are
in agreement with previous data showing that the calcium-
dependent release is not modified in SV2A KO chromaffin cells
(Xu and Bajjalieh, 2001). On the contrary, SV2B could perform
such function as its absence in cultured rod cells of the retina
induces an increase in presynaptic Ca2+ concentration (Wan
et al., 2010). Finally, the fact that insulin release is decreased
after SV2A or SV2C silencing in INS-1E cells (Iezzi et al.,
2005) is an argument in favor of a glucose receptor function.
A recent study shows that the expression of human SV2A in
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FIGURE 1 | Schematic view of post synaptic currents (PSC) and summary of Synaptic vesicle proteins 2A (SV2A) KO phenotype. (A) Spontaneous PSC
or sPSC: an action potential in the presynaptic neuron (black) induces a sPSC in the postsynaptic neuron (brown). (B) Miniature PSC or mPSC: the generation of
action potentials is blocked by Tetrodotoxin (TTX). If SVs exocytosis is functional, a single vesicle is release by the presynaptic neuron (black) and induces a mPSC in
the postsynaptic neuron (brown). The mPSC reveals thus the “molecular machinery” of SV exocytosis while sPSC also reveals the link between vesicle exocytosis
and the pre-synaptic action potential. (C) Evoked PSC or evoked postsynaptic currents (ePSC): an action potential is induced with an electrode (blue) in the
presynaptic neuron (black). The postsynaptic neuron (gray) responds by producing an ePSC. In comparison to the sPSC, the ePSC recruits the maximal possibilities
of SVs exocytosis. The analysis of SV2A KO phenotype is telling us that: (1) in physiological conditions, inhibitory PSC are affected negatively by the SV2A absence,
both in amplitude and in frequency although excitatory PSC are modified only through increased frequency; (2) the absence of SV2A does not interfere with the
molecular mechanism of the SV exocytosis process; and (3) when the synapse is pushed at its maximum of activity, both excitatory and inhibitory PSC are
decreased in amplitude.
hexose transport-deficient yeast restored the growing capacity
on a galactose-only medium. Moreover, a significant uptake of
galactose could be quantified in human SV2A-expressing yeasts
(Madeo et al., 2014). The role of carbon hydrates has been
increasingly noted over the last decade. Indeed, carbohydrates,
including glucose and galactose, contribute to the development
but also to proper functions of the nervous system through
glycosaminoglycans, which are implicated in proteoglycan (PG)
formation. PG could have a role in axon guidance, pathfinding,
and synapse formation but also in plasticity, or injury recovery
(Zhang et al., 2006; Um and Ko, 2013; Silver and Silver, 2014;
Smith et al., 2015; Takeda-Uchimura et al., 2015). In this regard,
SV2A as hexose transporter could play a crucial role in the
nervous system.
Gel Matrix
Although SV2A may not be a neurotransmitter transporter, it
could play a role in neurotransmitter concentration and release
by forming an intravesicular gel matrix. Indeed, in mast cells,
it has been shown that serotonin is restrained in vesicles by an
intragranular matrix, slowing its mobility and limiting its release
more than pore diameters would (Alvarez de Toledo et al., 1993;
Nanavati and Fernandez, 1993; Marszalek et al., 1997). Actually,
acetylcholine and ATP found in SVs of the Torpedo electric organ
seem to be fully released only when challenged with high NaCl or
KCl concentrations, suggesting the existence of a charged matrix
(Reigada et al., 2003). SV2A being the main Keratan-Sulfate
proteoglycan (KS-PG) of those SVs with all glycans located in
their lumen (Feany et al., 1992; Scranton et al., 1993), could be
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 May 2017 | Volume 10 | Article 148
Bartholome et al. Puzzling Out SV2 Proteins Functions
FIGURE 2 | Summary of neurophysiological observations. WT condition (black box): at cellular level (blue box), inhibitory postsynaptic currents (IPSC) and
EPSC of inhibitory neurons (in red) and excitatory neurons (in green) display characteristic amplitudes and frequencies. At tissue level (purple box), the inhibitory
frequency is higher than the excitatory frequency to moderate global input. SV2A KO condition (brown box): at cellular level (blue box), amplitudes of IPSC and EPSC
are reduced. At tissue level (purple box), the excitatory frequency is higher than the inhibitory frequency, leading to seizure onset and epilepsy.
a likely candidate to support this role. Moreover, SV2A needs at
least one N-glycosylation site available to be correctly targeted
to synapses (Kwon and Chapman, 2012), indicating that glycans
appear to be necessary for a proper SV2A function even if their
exact role in this matter needs to be defined. In addition, isolated
SVs filled with glutamate are bigger than empty ones, and those
lacking SV2A do not present such change (Budzinski et al., 2009).
However, previous studies have shown that SVs from SV2A KO
mice do not differ in size compared to those in WT (Crowder
et al., 1999; Janz et al., 1999; Custer et al., 2006). The fact that
Budzinski et al. (2009) work on isolated SVs could explain this
difference in their observations. In the absence of further inputs
on this matter, it is difficult to conclude anything regarding this
hypothesis.
SV2A and Synaptotagmin
Bennett et al. (1992) immunoprecipitated SVmembrane proteins
by different methods and shed light on possible interactions that
SV2A might have with other membranous synaptic proteins.
Using three different detergents (CHAPS, octylglucoside and
Triton X-100), they showed that SV2A could be in a complex
with synaptotagmin 1 (Syt1 or p65), synaptophysin (Syp or
p38) or Ras-related protein (rab3A; Bennett et al., 1992). Since
then, a lot of efforts have been made to identify protein
species that bind to SV2A. While little evidence has been
found in favor of a real interaction between Syp or rab3A
and SV2A, the link between Syt1 and SV2A has rapidly
been established. Despite early studies showing an absence of
interaction between SV2A and Syt1 (Chapman et al., 1998;
Littleton et al., 1999), it is now clear that all SV2 paralogs
bind to Syt1 (Schivell et al., 1996, 2005; Lazzell et al.,
2004).
In the pre-synaptic region, synaptotagmin is found on SV
and triggers the calcium-dependent exocytosis by binding Ca2+
on two C2 domains, quickly followed by the penetration of
those domains into the targeted cellular membrane (Brose et al.,
1992; Bai et al., 2002). This interaction of Syt1 with the plasma
membrane induces a bending of the membrane, allowing the SV
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to complete fusion (Martens et al., 2007; Hui et al., 2009). Syt1 is
found in most brain areas but is particularly expressed in rostral
parts (Geppert et al., 1991; Xu et al., 2007).
It is interesting to note that the interaction of SV2 proteins
with Syt1 seems highly controlled. First, the domain in all
SV2 that binds Syt1 is negatively regulated by calcium as
an increase in calcium concentration reduces the amount of
SV2 immunoprecipitated with GST-Syt (Schivell et al., 2005).
This observation corroborates the fact that the normalization
of the elevated calcium concentration in SV2B KO rod cells
restores normal neurotransmission (Wan et al., 2010). On the
other hand, another study reports that the binding of SV2B
to Syt1 in terminals of photoreceptor cells is not calcium-
dependent. However, the range of tested concentrations was
smaller compared to Wan’s studies, therefore the inhibitory
effect could have been missed (Lazzell et al., 2004). The
exact localization of the binding site is not known but
should include residues 56–74, as antibodies directed against
this region prevent the interaction between SV2B and Syt1
(Schivell et al., 1996, 2005). Second, SV2A and SV2C have
an additional binding site that is positively regulated by
calcium. This supplementary site could further modulate the
interaction with Syt1 (Schivell et al., 2005). Third, the amino-
termini of SV2A could be highly phosphorylated by members
of the casein kinase 1 family, increasing the affinity of
SV2A for Syt1 (Pyle et al., 2000). The N-terminal of SV2A
features two phosphorylated clusters but only Threonine 84 of
SV2A seems essential for binding since it forms hydrogen
bonds with three conserved Lysine residues of the C2B
domain of Syt1 (Zhang et al., 2015). Protein BLAST of
SV2 proteins shows that this Threonine is conserved in all
SV2 paralogs1.
While little evidence has been provided to confirm a role
for SV2A in vesicle priming as discussed above, another
hypothesis has emerged arguing that SV2A seems to have two
functions regarding Syt1. Reduction or overexpression of SV2A
induces a reduced or increased abundance of Syt1 respectively,
implying that SV2A could regulate Syt1 expression and/or
degradation. In addition, SV2A participates in the internalization
of Syt1 as its absence raises Syt1 concentration in the cellular
membrane (Yao et al., 2010; Nowack et al., 2011; Kaempf et al.,
2015).
Interestingly, the mutation of one residue in the first
endocytosis motifs in the amino-termini of SV2A does not affect
the overall capacity of SV2A to bind Syt1, supporting the idea
that the additional amino-binding site is not the main one (Yao
et al., 2010). On the other hand, the same mutation shows a
decrease of interactions with the clathrin adaptor AP-2 compared
to wild-type. AP-2 is known to bind to Syt1 at residues close
to those involved in SV2A binding (Haucke et al., 2000), and
immunoprecipitation studies show that AP-2, Syt1 and SV2A
can form a tripartite complex in rat brains (Haucke and De
Camilli, 1999). Since the SV2A key-residue for Syt1 binding
is Threonine 84 and the one potentially implicated in AP-2
binding is Tyrosine 46, SV2A could therefore be considered
1https://blast.ncbi.nlm.nih.gov/Blast.cgi
as an intrinsic trafficking partner (iTRAP) to facilitate AP-2
and Syt1 interactions (Figure 3; Gordon and Cousin, 2016).
These observations underline the similarity between SV2A and
another protein implicated in Syt1 retrieval, Stonin-2 (Stn2).
Indeed, this protein is able to interact both with Syt1 (primarily
by its C2A domain) and the ear domain of the α subunit
of AP-2 (Diril et al., 2006). In such a model, either AP-2
would then bind Syt1 via its C2B domain forming a multimeric
complex or Stn2 would deliver Syt1 to AP-2 (Jung et al.,
2007).
Interestingly, while the mutation of Stn2 ortholog in
invertebrates (in which SV2A do not exist) is lethal (Fergestad
et al., 1999;Mullen et al., 2012), it is not the case for Stn2KOmice
which are perfectly viable and fertile (Kononenko et al., 2013).
This fact is in agreement with the hypothesis that SV2A could be
implicated in an alternative pathway to Syt1 recycling, required
to safeguard or to refine the sorting of SV in the central nervous
system of vertebrates (Kaempf et al., 2015). This possibility is
strengthened by the fact that SV2A KO mice display elevated
levels of Stn2, and that the combined absence of SV2A and
Stn2 is responsible for an aggravated phenotype (Kaempf et al.,
2015).
Nonetheless, the fact that certain SV2A mutants failed to
rescue synaptic depression of neurotransmission observed in
SV2A KO neurons, while displaying normal Syt1 concentration
on the plasma membrane (Nowack et al., 2010), suggests that
the Syt1 recycling role might not be primary for SV2A and that
this protein could potentially perform other function(s) at the
synapse.
Other Leads on SV2A Functions
A photoaffinity labeling study revealed that SV2A, SV2B
and probably SV2C are able to bind adenine nucleotides,
particularly adenosine triphosphate (ATP) and nicotinamide
adenine dinucleotide (NAD). SV2A has two binding sites
located in the N-terminus: upstream the first TM domain and
in the large intracytoplasmic loop (Figure 4). Although this
observation may bring SV2A closer to the MFS family, neither
ATP nor NAD transport activities were detected (Yao and
Bajjalieh, 2008). Interestingly, SVOP is also able to bind adenine
nucleotide (particularly NAD) via its C-terminal extremity (Yao
and Bajjalieh, 2009) and Glut1 (a glucose transporter, another
MFS member) features a nucleotide binding site as well. The
site is located around TM domains 8 and 9 and negatively
regulates the glucose transport activity of Glut1 as it allows
Glut1 to be active only if ATP is depleted (Levine et al.,
1998, 2002). Like Glut1, SV2 proteins could be regulated or,
alternatively, could need adenine nucleotide bindings to perform
their functions. As the majority of experimental studies of SV2A
functions were performed as close to physiological conditions as
possible, it is more likely that the adenine binding has a positive
action on SV2A functions than the opposite. The presence of
a nucleotide binding site on SV2A could provide a modulatory
link between energy levels of the cell and its vesicle secretion
mechanism.
Another feature of SV2A, and SV2 paralogs in general, is that
they are involved in botulinum neurotoxins A and E (BoNT/A,
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FIGURE 3 | Interaction model of SV2A and Stonin 2 with Synaptotagmin 1. (A) After fusion event, the C2B domain of Synaptotagmin 1 (green) interacts with
SV2A (light blue) phosphorylated-T84 residue (orange) and Stonin 2 (dark blue) binds to both C2 domains of Synaptotagmin to initiate recycling. (B) SV2A and Stonin
2 bind to AP-2 (pink) to facilitate the formation of the endocytosis complex. (C) Synaptotagmin 1 binds to AP-2. Dephosphorylated SV2A keeps interaction with
AP-2 to consolidate the endocytosis complex. (D) After endocytosis, the fusion competent vesicle presents Synaptotagmin 1 bond again to T84-phosphorylated
SV2A. IC, Intracellular; EC, Extracellular.
BoNT/E) entrance into the cell. They are not the only synaptic
protein involved in BoNT entrance, as SYT1 and SYT2 are
also receptors for BoNT/B and BoNT/G neurotoxins (Verderio
et al., 2006). BoNTs are a family of compounds produced by
the bacteria Clostridium botulinum and are able to interfere with
neurotransmission. Depending on the sub-type, the toxin will
cleave the synaptosome-associated protein (SNAP-25), vesicle-
associated membrane protein (VAMP or synaptobrevin) or
syntaxin (Tighe and Schiavo, 2013). Cultured hippocampal
neurons invalidated for SV2A and SV2B do not bind BoNT/A.
Binding is restored by re-expression of SV2A, SV2B or SV2C
and is mediated by the luminal domain (L4). SV2C exhibits the
highest affinity for BoNT/A (Dong et al., 2006). More precisely,
one glycosylated asparagine present in the center of the interface
between SV2 and the toxin (residue 573 in SV2A, 516 in SV2B
and 559 in SV2C) seems to be implicated in BoNT/A’s mode
of entry (Mahrhold et al., 2016; Yao et al., 2016). Interaction
studies of SV2C with BoNT/A suggest an efficient and rapid
binding/unbinding of the pairmediated by the backbone of SV2C
rather than a side-chain interaction, as Syt1 and Syt2 do for
BoNT/B and G. Interestingly, the binding of SV2C to BoNT/A
is facilitated at pH 5, close to SV conditions, whereas the
binding of Syt2 with BoNT/B is pH-independent (Weisemann
et al., 2016). BoNT/A, BoNT/E failing to penetrate SV2A/B
DKO neurons appears to be quite logical as the interaction
of BoNT/E is mediated by the L4 domain of SV2A and B
exclusively. It is worth noting that chimeric SV2C-L4 domain
does not bind BoNT/E and displays a higher molecular weight,
suggesting additional glycosylation sites that might counteract
BoNT/E interaction. Moreover, glycosylation at N573 of SV2A
is essential for BoNT/E binding (Dong et al., 2008). Interestingly,
a single-point mutation of SV2A N-glycosylation site produces
a protein that is correctly localized to synapses and properly
recycled, suggesting that the failed internalization of BoNT/E is
due to an impaired binding (Kwon and Chapman, 2012). Finally,
SV2 proteins are also capable of BoNT/D binding by an unknown
mechanism independent of the L1, L3 or L4 domain (Peng et al.,
2011).
SV2A IN THE PATHOPHYSIOLOGY OF
NEUROLOGICAL DISEASES
SV2A and Epilepsy
Because SV2A KO mice display spontaneous and violent
seizures, and as the anti-epileptic drug Levetiracetam (LEV—also
known as Keppra©) targets SV2A (Lynch et al., 2004),
many studies have addressed the possible role(s) of SV2A
in various pathological conditions, particularly in epilepsy
pathophysiology.
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FIGURE 4 | Primary structures of SV2 proteins. In green: Synaptotagmin 1 binding domain. In blue: nucleotide binding domains. In orange: residues implicated in
LEV binding. Purple lozenge: phosphorylated residues. Pink square: glycosylated residues. In red: residues of particular interest. EC, Extracellular; IV, Intravesicular;
IC, Intracellular. (This figure was built using http://wlab.ethz.ch/protter/start/).
Thanks to the availability of resected tissues from human
brains after surgical treatments for pharmacologically-resistant
epilepsies, several teams had the opportunity to analyze SV2A
expression in such conditions. In temporal neocortices from
patients with intractable temporal lobe epilepsy (ITLE), western
blot quantifications revealed that SV2A is reduced by 40%
compared to human brains lacking an epileptic focus (Feng
et al., 2009). A comparable decrease (30%) is found in resected
hippocampi from patients suffering from TLE combined with
hippocampal sclerosis (HS). This is shown by a reduced labeling
in the hippocampus except in the inner layer of the DG
(van Vliet et al., 2009). In addition, resected tissues from
two other causes of ITLE, focal cortical dysplasia (FCD) or
tuberous sclerosis complex (TSC), also showed a reduction of
SV2A expression. If FCD or TSC were combined with HS,
SV2A was also reduced in the hippocampus (Toering et al.,
2009). Interestingly, mesial temporal sclerosis (MTS) type 1A,
also known as ‘‘classical hippocampal sclerosis’’, presents both
a downregulation of SV2A and an upregulation of SV2C
(Crèvecœur et al., 2014). A similar finding has been made in vitro
in chromaffin cells as compensation of SV2C in SV2A KO cells
reaches almost wild-type levels of total SV2 proteins (Xu and
Bajjalieh, 2001). This is of a particular interest in the context
of TLE as the majority of epileptic foci occur near or inside
the hippocampus where SV2C could potentially compensate for
SV2A absence.
As a significant proportion of patients with glioma
experiences focal epilepsy, the presence of SV2A was also
investigated in tumoral and peritumoral tissues. Surprisingly,
the level of expression was identical in patients suffering from
epilepsy and in those who didn’t (de Groot et al., 2010). This
challenges the role of SV2A in epileptogenesis, at least in these
cases. It is worth noting that the first homozygous mutation of
SV2A to be described in human was recently associated with
intractable epilepsy, involuntary movements, microcephaly and
developmental and growth retardations (Serajee and Huq, 2015).
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 May 2017 | Volume 10 | Article 148
Bartholome et al. Puzzling Out SV2 Proteins Functions
Both parents carry a variant allele, implying a recessive status,
while no other mutations in the exome could explain the child’s
phenotype.
All these observations highlight a potential neuroprotective
role for SV2A, as its absence appears to facilitate the progression
of epilepsy. In the hippocampus, a possible combination effect of
unbalanced levels of SV2A and SV2C could also be implicated.
However, since neuronal losses can be observed in TLE, further
studies are needed to clarify the exact role of SV2A in epileptic
pathophysiology.
From an experimental point of view, different animal models
have also been studied. In chronic epileptic rats resulting
from maximal electroshock (MES), SV2A levels decreased by
30%, which is similar to the reduction observed in human
patients suffering from TLE-HS. In contrast, no difference
could be seen between controls and rats which did not
develop progressive forms of epilepsy after MES induction.
More precisely, 1 day after status epilepticus (SE) occurred
in rats, SV2A labeling faded out in the inner layer and the
hilus of the DG. One week after SE, SV2A was reduced
in CA regions and could barely be observed in DG. In
chronic epileptic rats, SV2A levels remain reduced in almost
all layers of the hippocampus even 6–8 months post-induction
(van Vliet et al., 2009). In spontaneous epileptic rats (SER)
which exhibit spontaneous and absence seizures without any
external stimulation(s), SV2A levels are lower in almost all
cortical regions and in the inner molecular layer of the
hippocampus. Moreover, Syt1 levels roughly follow the same
pattern. Interestingly, analysis of neuronal densities revealed no
significant differences between SER and control rats (Hanaya
et al., 2012), excluding a correlation between cell loss and SV2A
decrease.
Contrasting with those observations, SV2A levels in the
hippocampus of electrically kindled rats were significantly
increased, as well as 7S SNARE complex expression (Matveeva
et al., 2007). Those elevated levels lasted for at least 1 year
(Matveeva et al., 2008). SV2A immunoreactivity was also
increased in hippocampi of PTZ-kindled mice while no change
was observed in the cortex or cerebellum. More precisely,
higher SV2A levels were localized in the hilus of DG, together
with GAD67 immunoreactivity, a GABAergic neuron marker
(Ohno et al., 2009, 2012). The authors hypothesize that the
increased concentration of SV2A in inhibitory neurons could
counterbalance seizure occurrences.
It is important to note that, as different types of epilepsy
exist, all animal models do not have the same characteristics.
This might explain the striking differences found in SV2A
levels. MES rat constitute a model close to SER as they keep
experiencing seizures (11 seizures per day in average), several
months after the last stimulation (van Vliet et al., 2009).
The lower levels of SV2A in both models could corroborate
the hypothesis that SV2A reduction is implicated in epilepsy
progression and/ormaintenance. In contrast, electrically-kindled
rats and PTZ-kindled mice models where higher levels of
SV2A are found, experience ‘‘evoked’’ seizures in response to
convulsing chemicals or mild electrical stimulations rather than
real spontaneous seizures (Sharma et al., 2007).
In 1999, Levetiracetam (LEV—commercial name: Keppra©)
was approved by the Food and Drug administration as a novel
anti-epileptic drug. It is particularly useful in patients suffering
from partial seizures, patients less responsive to conventional
drugs or showing risks of drug interactions (Hovinga, 2001).
Even if the exact mechanism by which LEV acts on seizures
is still undefined (we don’t even known if LEV is an agonist
or antagonist of SV2A), we know that it binds to SV2A and
that this binding is required for its anti-epileptic action (Lynch
et al., 2004). Implicated residues in this binding are depicted
in Figure 4 (Shi et al., 2011; Lee et al., 2015). It is worth
noting that LEV is able to normalize under- and over-expression
of SV2A in autaptic hippocampal neurons by controlling the
concentration of SV2A in the synapse (Nowack et al., 2011).
More recently, other compounds were added to the racetam
family—Brivaracetam, Selectracetam—and show promises for
epilepsy therapeutic control. Those molecules also bind SV2A
(Gillard et al., 2011; Rogawski, 2016). As the link between SV2A
and LEV was very recently extensively reviewed (Löscher et al.,
2016), we will not further elaborate.
SV2A and Other Neurological Diseases
Besides epilepsy, SV2A could also be involved in the
pathophysiology of other neurological diseases. In 1996,
SV2A was identified in dystrophic neurites around neuritic
plaques of Alzheimer’s disease (AD) patients and normal
aged brains. In contrast, no traces of SV2A were found in
tangles, amyloid deposits or diffuse plaques in AD or normal
aged brains (Snow et al., 1996). When it was demonstrated
that hyper-excitability of hippocampal neurons could play
an important role in the development of AD (Bookheimer
et al., 2000; Dennis et al., 2010; Quiroz et al., 2010), the effect
of LEV on amnestic mild cognitive impairment (aMCI) was
investigated. A first study revealed that under low doses
treatment, LEV was able to normalize hippocampal activation
level and seemed to improve cognitive tasks (Bakker et al., 2012).
In addition, immunoprecipitation studies of brain extracts
showed an interaction between Amyloid Beta A4 Precursor
Protein-binding Family B Member 1 (FE65) and SV2A (Nensa
et al., 2014). Co-transfection of FE65 and SV2A modifies the
FE65 distribution in the cytoplasm, suggesting an effect of
SV2A on FE65 intracellular targeting. In parallel, combined
proteomic and transcriptomic studies of brain organelles show
that SV2A was 22 times more expressed in mitochondria
compared to microsomes and the cytosol (Kislinger et al., 2006).
Mitochondria dysfunction is another parameter that can take
part in AD development (Swerdlow, 2012). Interestingly, SV2A
was also localized in mitochondria of aging and late-onset AD
cell models (Stockburger et al., 2016). In the samemodel, positive
effects of LEV treatment on the mitochondrial fission and fusion
balance were abolished if SV2A expression was invalidated by
siRNA.
SV2B also seems to be affected in AD. SV2B gene expression
is down regulated in hippocampi and neocortices of AD patients
compared to control (Gómez Ravetti et al., 2010; Tan et al.,
2010). Moreover, SV2B (along with other genes involved in
synaptic plasticity, vesicle fusion or docking) is down-regulated
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in hippocampi of AD cases with expression of APOE alleles
associated with higher risks of early AD onset compared to other
AD patients (Xu et al., 2006). On the contrary, neurons exposed
to amyloid beta peptides (Aβ) specifically overexpress an mRNA
transcript variant of SV2B with an elongated 3′UTR. The authors
suggest that this change could be involved in neurodegeneration
progression (Heese et al., 2001). This observation is confirmed
by the fact that in SV2B KO mice, the effect of an oligomeric
preparation of Aβ25–35 is strongly reduced (Detrait et al., 2014).
Schizophrenia (SCZ) is another disorder that has been
recently suspected to involve SV2A in its pathophysiology
pathway. Genomic analysis of several cerebellar cortices from
patients suffering from SCZ revealed an alteration of numerous
synaptic transport proteins, SV2A being one of them (Mudge
et al., 2008). Furthermore, a single nucleotide polymorphism
(SNP) in the SV2A gene region was found to be significantly
associated with SCZ. SV2A gene is surrounded by histone
gene clusters, known to be linked to SCZ. Therefore, further
studies are needed to clarify which gene is influenced by
the SNP (Mattheisen et al., 2012). Interestingly, a novel drug
devoid of anticonvulsant properties (UCB0255) and acting as
a negative modulator of SV2A, seems to increase the cognitive
capacity in the sub-chronic phencyclidine (PCP) rat model.
This rat line exhibits typical SCZ parameters like low prefrontal
dopamine, low prefrontal metabolism and enduring cognitive
deficits (Laruelle et al., 2014).
COULD ALL SV2 PROTEINS ENDORSE
THE SAME ROLE?
The discovery circumstances of SV2 proteins give the illusion
that SV2 proteins are isoforms. It is now known that SV2 proteins
have their attributed genes on different chromosomes (Table 1)
and that they arose from duplication events that may have taken
place around the apparition of vertebrates, making them paralogs
(Figure 4).
At first, the absence of any phenotype in SV2B KO mice
suggested that the role of SV2B was different from the one of
SV2A. But the fact that SV2B is able to rescue synaptic depression
in cultured neurons proves that SV2A and SV2B share at least
one role in neurotransmission (Nowack et al., 2010). This is
surprising because SV2B KO mice do not exhibit even mild
neurotransmission problems. Indeed, they are usually used as
controls in SV2A/B DKO experiments. Several SV2B features
could explain this situation. First, the distribution pattern of
SV2B is slightly narrower compared to SV2A. If the severity
of SV2A KO phenotype is driven by the fact that it impacts
virtually all synapses of the brain, it may seem logical that
SV2B KO mice would be less or not affected. On the other
hand, seizures could typically arise after the development of
an epileptic focus corresponding to either localized or broader
brain regions: no proof has been provided yet to demonstrate
whether or not SV2A could induce partial or simple seizures. It
has been proposed that the normal phenotype of SV2B KO mice
is due to an overall lower expression level of SV2B compared to
SV2A (Nowack et al., 2010). Indeed, in the vast majority of the
brain, SV2A reaches a higher expression level than SV2B, but
more importantly SV2B is expressed primarily in glutamatergic
synapses whereas SV2A can be found in both networks. This
means that SV2A and SV2B could compensate each other’s
absence only in glutamatergic synapses. Rod photoreceptor cells
are one of the few neuronal cell types where SV2A has a faint
expression whereas SV2B is highly concentrated. SV2B KO mice
display reduced b-wave amplitude at rod synapses, indicating
that SV2B loss could induce a decrease in neurotransmission
(Wang et al., 2003; Morgans et al., 2009) as SV2A absence does.
Finally, cortical and hippocampal glutamatergic networks seem
to be less affected by SV2A absence than GABAergic ones and
the combined absence of SV2A and B does not seem to drastically
alter neurotransmission. For this reason, a SV2 defect affecting
the GABAergic networks appears more effective than the same
defect targeting the glutamatergic networks.
Given the peculiar distribution pattern of SV2C, this paralog
was immediately considered to differ from the two others. Very
few studies have been performed on SV2C but the generation
of SV2C KO mice will provide a useful tool to assess its
potential role (Dardou et al., 2011). These mice present an
upregulation of tyrosine hydroxylase mRNA combined with
downregulation of encephalinmRNA. After 6-hydroxydopamine
and MPTP-induced lesions (two experimental models of
Parkinson’s diseases), SV2CmRNA levels increased significantly.
SV2C KO mice seem to present slightly less exploratory and
slightly more anxious behavior (Dardou et al., 2013). In parallel,
an association study on the genome of human and Drosophila
revealed that SV2C could be implicated in PD through its
potential role in nicotine neuroprotection (Hill-Burns et al.,
2013). More recently, a team showed that SV2C interacts with
α-synuclein in mouse homogenates and that SV2C KO mice
exhibits reduced level of dopamine release. Moreover, brain
sections of patients suffering from Parkinson’s diseases also seem
to display more SV2C-positive labels than normal aged brains
(Dunn et al., 2017).
CONCLUSIONS
Even if more and more data are gathered on SV2A, its exact
function is still a matter of debate.
In hippocampal or cortical neuronal cell populations, loss
of SV2A leads to synaptic facilitation and to the reduction of
post-synaptic currents amplitude at least in excitatory synapses.
The possibility that the RRP of SVs is affected in SV2A KO is still
discussed (Custer et al., 2006; Chang and Sudhof, 2009). If indeed
this is the case, one could recall a priming defect, reinforced
by the reduction of SDS resistant SNARE complex as seen in
SV2A-deficient chromaffin cells or by the combined increase of
7S SNARE complex and SV2A as seen in PTZ-induced mice
(Xu and Bajjalieh, 2001; Matveeva et al., 2008). If it is not the
case, a decreased capacity to trigger synaptic release could be
evoked, which is consistent with the Syt1 recycling function of
SV2A in parallel with Stn2 (Nowack et al., 2010; Yao et al.,
2010; Kaempf et al., 2015). Moreover, the fact that the absence of
SV2A induces an increased recycling of Syt1 different from the
clathrin-mediated recycling after a train of stimulations (Zhang
et al., 2015), could participate to the facilitation phenotype. This
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 May 2017 | Volume 10 | Article 148
Bartholome et al. Puzzling Out SV2 Proteins Functions
increased recycling is also produced by the absence of Stn2,
as well as following mutation of the binding site on SV2A,
Syt1 or the overexpression of Syt1 (Kononenko et al., 2013;
Zhang et al., 2015). The distribution of Stn2 has never been
deeply investigated but the protein seems to be expressed in most
parts of the brain and particularly in the hippocampus (Walther
et al., 2001, 2004), matching the ubiquitous distribution of SV2A.
The fact that SV2A-R231Q rescues neurotransmission defects
in SV2A KO without correcting the accumulation of Syt1 usually
observed in SV2A absence, suggests that SV2A main function is
not the recycling of Syt1 (Nowack et al., 2010). Finally, glycans
present on the L4 domain of SV2A could serve as vesicular
matrices but strong evidence supporting this affirmation is
lacking (Reigada et al., 2003).
In mice, absence of SV2A leads to early death after
epileptic seizures and seems to cause a reduction of inhibitory
post-synaptic current frequencies and an augmentation of
excitatory post-synaptic current frequencies, reversing the
normal balance between those two inputs (Venkatesan et al.,
2012). On the other hand, rats with a mutated form of SV2A
are more susceptible to PTZ treatment and present a reduction
of depolarization-induced GABA release in the hippocampus
and the amygdala but no changes in depolarization-induced
glutamate release (Tokudome et al., 2016a,b), linking again
specifically SV2A with the GABAergic network. This is truly
surprising as the presence of SV2A in glutamatergic synapses
has been proven by a broad range of techniques. Still in any
case, the fact that no change in glutamate release was observed
is surprising as excitatory frequencies seem to be increased due
to inhibitory frequency reductions.
In some epileptic patients and ‘‘long-term’’ animal models of
epilepsy, a significant reduction of SV2A is observed, supporting
the idea that SV2A could endorse a role in epilepsy progression
(Feng et al., 2009; Toering et al., 2009; van Vliet et al.,
2009; Hanaya et al., 2012). In ‘‘short-term’’ animal models of
this disease, SV2A is overexpressed suggesting a compensatory
phenomenon (Matveeva et al., 2007, 2008; Ohno et al., 2009,
2012).
More and more observations bring SV2A and SV2B closer as
they appear to compensate each other in vitro and as both seem
to be implicated in AD. Based on observations of SV2A, SV2B
and SV2A/B KO mice, it seems that in glutamatergic neurons
the presence of SV2B allows to compensate SV2A absence. The
low level of SV2B in GABAergic cells would then favor a link
between SV2A loss and seizures development. As an alternative
explanation, one (or several) unknown protein(s) could be able to
compensate SV2A and SV2B absences in glutamatergic synapses
only, reducing the impact of SV2 absence on this network
compared to the GABAergic system. This wouldn’t be the case
in retinas, explaining the severe defect associated with SV2B
absence in this structure. It is unlikely that this role could be
assumed by Stn2 because a SV2A mutants do elicit normal
Syt1 recycling and still induce neurotransmission problems
(Nowack et al., 2010).
There are a lot of answers needed to deepen the understanding
of SV2 functions and mechanisms. First, given the number
of common points between Stn2 and SV2A, it would be
interesting to compare their expressions, searching for a
correlation in Stn2/SV2A ratios between different cell types,
synapse types or brain regions. Second, considering the fact that
SV2A overexpression in cultured neurons presents the same
neurotransmission modifications and/or impairments than its
absence (Nowack et al., 2011), overexpressing SV2A in animal
models could be interesting and provide information on a largely
underexplored field. Next, comparing the proteomic content of
vesicles obtained from glutamatergic synapses in different parts
of the brain could shed light on the potential compensation of
SV2A and/or SV2B absence in glutamatergic neurons. Finally,
following Tukodome’s group recent articles, the impact of SV2A
absence in different cell types on seizures onset is still unclear and
requires additional observations. To this aim, a newmousemodel
based on the cre-lox system (Menten-Dedoyart et al., 2016) will
allow the invalidation of SV2A in specific inhibitory neuron
populations and a comparison of obtained phenotypes with those
where SV2A is absent in excitatory neuron populations. This
research effort could also bring answers and explanations to
several electrophysiological differences observed in SV2A KO
phenotypes.
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